Vroegindeweij 1997.

Methods	Study design: RCT Method of randomisation: Concealed randomisation using sealed randomisation envelopes. Blinding: Unblinded, intention‐to‐treat. Exclusions post‐randomisation: None. Losses to follow‐up: None. Cross‐over to stenting in PTA group: 4.
Participants	Country: The Netherlands. Setting: Hospital. No. of participants: 51 (51 limbs). Age (mean): 64.5 years. Gender: 36 men, 15 women. Inclusion criteria: Lesions confined to femoropopliteal artery. Exclusion criteria: Below‐knee popliteal disease; multisegmental disease; disease > 5 cm in length.
Interventions	PTA (27): over the wire. Stent (24): stainless steel 'Palmaz'. 5000 iu heparin intraoperative. 3 months warfarin.
Outcomes	6 weeks, 3, 6, 9, 12, 18 and 24 month follow‐up: ABI, treadmill test, duplex ultrasound. Primary patency defined as proximal peak velocity ratio > 2.5 on duplex ultrasound.
Notes	Runoff vessel patency at time of intervention unclear. Participants with coexisting ipsilateral proximal arterial stenosis included. Sponsor: No statement.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Concealed randomisation using sealed randomisation envelopes.
Allocation concealment (selection bias)	Low risk	Concealed randomisation using sealed randomisation envelopes.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Impossible in this type of trial.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated but radiological investigations would show stent placement.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No statement on attrition.
Selective reporting (reporting bias)	Low risk	All outcomes accounted for.
Other bias	Unclear risk	Warfarin used initially then unclear medication protocol.